Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 7/20 | 0.89 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.89 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.89 |
| ▸ | PGR | P06401 | 3/20 | 0.89 |
| ▸ | TSHR | P16473 | 2/20 | 0.89 |
| ▸ | AR | P10275 | 2/20 | 0.89 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.89 |
| ▸ | MEN1 | O00255 | 1/20 | 0.89 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.89 |
| ▸ | APEX1 | P27695 | 1/20 | 0.89 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.89 |
| ▸ | IKBKB | O14920 | 1/20 | 0.89 |
| ▸ | CHUK | O15111 | 1/20 | 0.89 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.89 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.89 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.89 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexamethasone SCHEMBL3836634 | 1.00 | HIF1A (0.89) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL13740162 | 0.98 | HIF1A (0.86) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL337333 | 0.98 | HIF1A (0.89) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL27582183 | 0.98 | HIF1A (0.89) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL1301201 | 0.97 | HIF1A (0.90) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL8508844 | 0.97 | HIF1A (0.90) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL7779 | 0.97 | HIF1A (0.90) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL6908689 | 0.97 | HIF1A (0.90) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL12099597 | 0.97 | HIF1A (0.89) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL5501682 | 0.96 | HIF1A (0.93) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107532201-B | Method for assessing response of patients with ataxia telangiectasia to glucocorticoid therapy | 爱瑞德勒股份有限公司 | 2021-05-11 | — | — | CN | claimed |
| US-20150297588-A1 | STERILE OTIC FORMULATIONS | Entrx LLC | 2015-10-22 | — | — | US | claimed |
| US-9849126-B2 | Sterile otic formulations | Entrx LLC (US) | 2017-12-26 | — | — | US | disclosed |
| US-20150297588-A1 | STERILE OTIC FORMULATIONS | Entrx LLC | 2015-10-22 | — | — | US | disclosed |
| WO-2014061937-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION COMPRISING PIPERACILLIN OR ITS SALT, TAZOBACTAM OR ITS SALT AND DEXAMETHASONE PHOSPHATE OR ITS SALT | YUHAN CORPORATION (KR) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014010924-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION COMPRISING VANCOMYCIN OR ITS SALT AND DEXAMETHASONE PHOSPHATE OR ITS SALT | YUHAN CORPORATION (KR) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297588-A1 | STERILE OTIC FORMULATIONS | IFNG, SPOUT1, IL1A | NR3C1 3414/4885HIF1A 55/4885CYP3A4 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.